MDGL Q2 2017 Earnings — Madrigal Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

MDGLMadrigal Pharmaceuticals, Inc.

$10B

Q2 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$8,000

Operating Income

-$8M

Net Income

-$8M

EPS (Diluted)

$-0.69

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$8M

Free Cash Flow

-$8M

Stock-Based Comp.

$676,000

Balance Sheet

Total Assets

$68M

Total Liabilities

$6M

Stockholders' Equity

$62M

Cash & Equivalents

$35M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$8,000	$0	—
Operating Income	-$8M	-$3M	-141.9%
Net Income	-$8M	-$3M	-190.1%